Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2025 08:00 ET | Source: Geron Corporation

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE...
December 08, 2025 08:02 ET | Source: Geron Corporation

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including...
October 13, 2025 16:34 ET | Source: Geron Corporation

Geron Corporation Announces Executive Leadership Transitions and Appointments

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,...
September 18, 2025 16:01 ET | Source: Geron Corporation

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an...
November 05, 2020 16:05 ET | Source: Geron Corporation

Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events

FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
July 01, 2020 08:30 ET | Source: Geron Corporation

Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes

Designation would provide 10-year period of marketing exclusivity in the European Union after product approvalPatients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk...
June 12, 2020 08:30 ET | Source: Geron Corporation

Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress

For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
May 28, 2020 16:05 ET | Source: Geron Corporation

Geron Corporation Reports First Quarter 2020 Financial Results

MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference...
May 27, 2020 16:30 ET | Source: Geron Corporation

Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants

MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced...
May 22, 2020 07:15 ET | Source: Geron Corporation

Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced...